The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...
4hon MSN
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback